Viatris employees rang the Nasdaq bell on Nov. 16, marking the one-year anniversary of the merged Mylan and Pfizer Upjohn company
Starting from scratch: Viatris’ new brand, culture settle in 1 year after Mylan, Upjohn merger
When Mylan and Pfizer’s Upjohn unit merged last year, headlines touted the $12 billion deal and newly named Viatris as the largest generic drugmaker in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
